inlyta - axitinib tablet, film coated
(Axitinib)U.S. Pharmaceuticals
Receptor Tyrosine Kinase Inhibitors [MoA] class drugs
5 results
inlyta - axitinib tablet, film coated
(Axitinib)Pfizer Laboratories Div Pfizer IncUsage: Inlyta (axitinib) treats advanced renal cell carcinoma (RCC): in combination with avelumab or pembrolizumab as first-line therapy, or as a single agent after failure of one prior systemic therapy.lenvima - lenvatinib capsule
(Lenvatinib)Eisai Inc.Usage: LENVIMA treats adults with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (with pembrolizumab or everolimus), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (with pembrolizumab) in pMMR or non-MSI-H patients who progressed after prior therapy.rydapt - rydapt capsule, liquid filled
(Rydapt)Novartis Pharmaceuticals CorporationUsage: RYDAPT treats adults with newly diagnosed FLT3 mutation-positive AML in combination with chemotherapy (not as single-agent induction), and adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).xalkori - crizotinib capsule
(Crizotinib)Pfizer Laboratories Div Pfizer IncUsage: XALKORI treats adults with ALK- or ROS1-positive metastatic non-small cell lung cancer; patients 1 year and older with relapsed or refractory ALK-positive anaplastic large cell lymphoma; and patients 1 year and older with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumor.